Evidence Level
Lemon balm has demonstrated moderate clinical support for its effects on stress, anxiety, sleep, and certain cardiometabolic parameters. Kennedy et al. (2004) found that 600mg of lemon balm reduced acute stress in a controlled setting. In an open-label study, Cases et al. (2011) reported significant reductions in anxiety by 49% and insomnia by 39% over 15 days with the Cyracos extract. Additionally, Kennedy et al. (2003) observed cognitive benefits alongside calming effects in participants.
The mechanism of action involves rosmarinic acid, which inhibits GABA transaminase, thereby increasing GABA availability (Awad et al., 2009). This effect is supported by in vitro studies. Furthermore, the combination of valerian and lemon balm has been studied in European trials for sleep support (Cerny & Schmid, 1999).
Recent systematic reviews and meta-analyses provide additional evidence. Ghazizadeh et al. (2021) analyzed eight RCTs involving 569 participants, concluding that lemon balm significantly reduced anxiety (SMD: -0.98) and depression (SMD: -0.47) scores compared to placebo, though with notable heterogeneity. Heshmati et al. (2020) reviewed seven RCTs (n=305), finding that lemon balm intake reduces total cholesterol (-0.26 SMD, p<0.05) and systolic blood pressure (-0.56 SMD, p<0.01). Shahsavari et al. (2024) conducted a meta-analysis of five RCTs involving 302 participants, showing that lemon balm significantly lowers triglycerides, total cholesterol, and LDL levels but does not affect HDL.
Overall, lemon balm has demonstrated efficacy in managing anxiety, depression, and certain cardiometabolic parameters, though further research is needed to address study heterogeneity and confirm long-term effects.